Network News

X My Profile
View More Activity
Column Archive |  On Twitter: J Huget and MisFits  |  Fitness & Nutrition News  |  RSS Feeds RSS Feed

FDA investigates diabetes drug's safety

Another widely used diabetes drug is under investigation for possible safety concerns.

The Food and Drug Administration announced Friday that it was reviewing data about the diabetes drug Actos because of concerns that it may increase the risk for bladder cancer.

The FDA stressed that at the moment there is no clear evidence that the drug increases the risk. But the agency said it was reviewing the situation.

Ironically, sales of Actos increased because of concerns about the safety of another similar drug, known as Avandia. In Avandia's case, the concern is that the drug may increase the risk for heart attacks. In July, a panel of FDA advisers issued a mixed verdict about whether Avandia should stay on the market.

Here's the FDA's statement:

The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

The preliminary results are based on five-year data from an ongoing, 10-year observational study by the manufacturer, Takeda Pharmaceuticals North America Inc., San Diego. These early results showed no overall association between Actos exposure and risk of bladder cancer. However, there was an increased risk of bladder cancer in patients with the longest exposure to Actos and in those with the highest cumulative dose of the drug.

At this time, the FDA's review is ongoing. The agency has not concluded that Actos increases the risk of bladder cancer.

Actos (pioglitazone) is used to control blood sugar in patients with type 2 diabetes mellitus. It is in the class of drugs known as peroxisome proliferator-activated receptor (PPAR) agonists. The only other drug in this class is Avandia (rosiglitazone). The FDA has no clinical information associating Avandia with bladder cancer in patients receiving that drug.

Patients should talk to their health care professional if they have concerns about Actos. They should not stop taking the drug unless told to do so by their health care professional.

By Rob Stein  | September 17, 2010; 2:10 PM ET
Categories:  Diabetes, FDA  
Save & Share:  Send E-mail   Facebook   Twitter   Digg   Yahoo Buzz   StumbleUpon   Technorati   Google Buzz   Previous: Katherine Schwarzenegger, Katie Couric on parents and self-esteem
Next: Could a childhood infection trigger obesity?


THe FDA has known about the dangerous of this drug for a long time. This drugs has serious side effects thaht the FDA knew about 5 years ago.

The drug makers have keep this drug on the market for the 4 BILLION DOLARS it takes in yearly.

A filmmaker has been reversing diabetes and obesity in now 10 countries but the drug companies do not promote the story

Posted by: healing1 | September 17, 2010 2:58 PM | Report abuse

Spirit Happy Diet = hustling book and report for $$$$. Cut back on your carbs if you are T2 and keep up the insulin if you are T1. There is no magic bullet at the moment. Borderline T2 is already treated with diet, free ones at that. It borders on criminality to tell people that diet alone can cure all diabetes. Bring back the snake oil.

Posted by: hc01 | September 17, 2010 4:26 PM | Report abuse

definetely,it is very true that major brands always give out free samples on health products check out tell your friends also

Posted by: quincyhow18 | September 18, 2010 4:03 AM | Report abuse

The comments to this entry are closed.

RSS Feed
Subscribe to The Post

© 2010 The Washington Post Company